Janssen Pharmaceuticals, Inc.

Boehringer Ingelheim Vetmedica Gmbh

Boehringer Ingelheim International Gmbh

Asta Medica, Aktiengesellschaft

Arzneimittelwerk Dresden Gmbh

Rita Dost

Hans-Joachim Lankau

Chris Rundfeldt

Barbara Langen

Ute Egerland

Norbert Höfgen

Rudolf Schindler

Klaus Unverferth

Simon Ward

Christian Grunwald

Wolfgang Loscher

Andrea Tipold

Reni Bartsch

Angelika Rostock

Christine Tober

Thorsten Hage

Hans Stange

Ure Egerland

Norbert Hoefgen

Wolfgang Loescher

The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.

Pyrazoles

Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B receptors.

Triazoles as NR2B receptor inhibitors

The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases. 

Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B receptors. 

The invention relates to (1,2,4)triazolo[4,3-a]quinoxaline derivatives which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases.

(1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases

The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.

Use of dihydroimidazolones for the treatment of dogs

The invention relates to the use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene of formula I ##STR1## or its pharmaceutically utilizable salts, for the prophylaxis and treatment of neuropathic pain.

Use of retigabine for the treatment of neuropathic pain

A process for the treatment of anxiety and tension, which comprises administering to a patient in need therefor an anxiolytically effective amount of a compound of the formula ##STR1## wherein X is hydrogen, a C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl residue, or halogen; R.sup.1 and R.sup.2 are independently of each other a C.sub.1-4 alkyl, cycloalkyl, C.sub.2-4 hydroxyalkyl, or heteroalkyl residue, or R.sup.1 and R.sup.2 together form a C.sub.2-6 alkylene residue in which one --CH.sub.2 -- group can be replaced by oxygen, nitrogen or sulfur; n is 0 or 1, and m is 0 or a cardinal number from 1-5, or a pharmaceutically acceptable salt of the compound.

Growing community of inventors

Dresden, Germany

Rita Dost